Improving lives through innovative medicines

new acquisition

F-star Therapeutics

On 9th March 2023, invoX announced that it has completed the acquisition of  F-star Therapeutics.  Founded in 2006, F-star is a clinical stage biotech in Cambridge, UK. F-star is dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy.

Read more

Our Team

Experience and expertise in the pharmaceutical industry, our team are dedicated and passionate to our work at invoX Pharma.

Meet our team

Please get in touch, it would be great to hear from you!